Efficacy and safety of caspofungin for patients with hepatic insufficiency
Abstract Background To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores. Methods In total, 200 patients (Child–Pugh A group: 66 patients, Child–Pugh B group: 83 patients, Child–Pugh C group: 51 pa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07527-8 |
| _version_ | 1828804900769759232 |
|---|---|
| author | Xiaoyun Ran Pengfei Wang An Zhang Binfei Tang |
| author_facet | Xiaoyun Ran Pengfei Wang An Zhang Binfei Tang |
| author_sort | Xiaoyun Ran |
| collection | DOAJ |
| description | Abstract Background To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores. Methods In total, 200 patients (Child–Pugh A group: 66 patients, Child–Pugh B group: 83 patients, Child–Pugh C group: 51 patients) treated with caspofungin from May 2018 to March 2021 in the Second Affiliated Hospital of Chongqing Medical University were enrolled. Main investigation items were as follows: sex, age, weight, duration of treatment, dosage, department, underlying diseases, risk factors for fungal infection, albumin, liver enzyme, total bilirubin, serum creatinine, estimated glomerular filtration rate. To investigate the changes of liver, kidney function tests and efficacy during the treatments of caspofungin. Patients were divided into three groups according to the duration of treatment of caspofungin:1-week group, 2-week group and 3-week group, respectively. Results In the three groups, albumin, liver enzyme levels, total bilirubin and serum creatinine, estimated glomerular filtration rate had no significant difference (P > 0.05). The efficacy of different Child–Pugh scores and different duration of treatment was also significantly different (P > 0.05). Conclusions Caspofungin is well tolerated and highly effective. And it will not exacerbate the hepatic and renal function when administered with the not-reducing dose, which indicate the clinical application value of caspofungin. Besides, extending the treatment duration has little effect on improving the efficacy of caspofungin. The drug should be withdrawn timely according to the patients’ clinical condition in order to reduce the adverse reactions and economic burden. |
| first_indexed | 2024-12-12T07:46:58Z |
| format | Article |
| id | doaj.art-aab0e9fb68c04e5081195831ee2e3179 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-12T07:46:58Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-aab0e9fb68c04e5081195831ee2e31792022-12-22T00:32:34ZengBMCBMC Infectious Diseases1471-23342022-06-012211710.1186/s12879-022-07527-8Efficacy and safety of caspofungin for patients with hepatic insufficiencyXiaoyun Ran0Pengfei Wang1An Zhang2Binfei Tang3Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical UniversityDepartment of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical UniversityDepartment of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical UniversityDepartment of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical UniversityAbstract Background To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child–Pugh scores. Methods In total, 200 patients (Child–Pugh A group: 66 patients, Child–Pugh B group: 83 patients, Child–Pugh C group: 51 patients) treated with caspofungin from May 2018 to March 2021 in the Second Affiliated Hospital of Chongqing Medical University were enrolled. Main investigation items were as follows: sex, age, weight, duration of treatment, dosage, department, underlying diseases, risk factors for fungal infection, albumin, liver enzyme, total bilirubin, serum creatinine, estimated glomerular filtration rate. To investigate the changes of liver, kidney function tests and efficacy during the treatments of caspofungin. Patients were divided into three groups according to the duration of treatment of caspofungin:1-week group, 2-week group and 3-week group, respectively. Results In the three groups, albumin, liver enzyme levels, total bilirubin and serum creatinine, estimated glomerular filtration rate had no significant difference (P > 0.05). The efficacy of different Child–Pugh scores and different duration of treatment was also significantly different (P > 0.05). Conclusions Caspofungin is well tolerated and highly effective. And it will not exacerbate the hepatic and renal function when administered with the not-reducing dose, which indicate the clinical application value of caspofungin. Besides, extending the treatment duration has little effect on improving the efficacy of caspofungin. The drug should be withdrawn timely according to the patients’ clinical condition in order to reduce the adverse reactions and economic burden.https://doi.org/10.1186/s12879-022-07527-8Hepatic insufficiencyChild–Pugh scoreCaspofunginDosageEfficacy |
| spellingShingle | Xiaoyun Ran Pengfei Wang An Zhang Binfei Tang Efficacy and safety of caspofungin for patients with hepatic insufficiency BMC Infectious Diseases Hepatic insufficiency Child–Pugh score Caspofungin Dosage Efficacy |
| title | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
| title_full | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
| title_fullStr | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
| title_full_unstemmed | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
| title_short | Efficacy and safety of caspofungin for patients with hepatic insufficiency |
| title_sort | efficacy and safety of caspofungin for patients with hepatic insufficiency |
| topic | Hepatic insufficiency Child–Pugh score Caspofungin Dosage Efficacy |
| url | https://doi.org/10.1186/s12879-022-07527-8 |
| work_keys_str_mv | AT xiaoyunran efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency AT pengfeiwang efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency AT anzhang efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency AT binfeitang efficacyandsafetyofcaspofunginforpatientswithhepaticinsufficiency |